Hematopoietic stem cell transplantation for solid tumors

Update on Cancer Therapeutics

Volumn 1, Issue 3, 2006, Pages 343-352

  Imanguli, Matin M ^a   Childs, Richard W ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Graft versus tumor effect; Solid tumors

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETOPOSIDE; FLUDARABINE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THYMOCYTE ANTIBODY;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BREAST CANCER; CANCER PATIENT; CANCER REGRESSION; CLINICAL TRIAL; COLON CANCER; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; KIDNEY CARCINOMA; MELANOMA; METASTASIS; NONHUMAN; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; OVARY CANCER; PANCREAS CANCER; PATIENT COMPLIANCE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SARCOMA; SOLID TUMOR; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 33748586748     PISSN: 1872115X     EISSN: 1872115X     Source Type: Journal    
DOI: 10.1016/j.uct.2006.08.003     Document Type: Review

References (44)

1. Gratwohl A., et al. Hematopoietic stem cell transplantation for solid tumors in Europe. Ann Oncol 15 4 (2004) 653-660
2. Ueno N.T., et al. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol 16 3 (1998) 986-993
3. Barrett J., and Childs R. Non-myeloablative stem cell transplants. Br J Haematol 111 1 (2000) 6-17
4. Goulmy E. Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. Immunol Rev 157 (1997) 125-140
5. Klein C.A., et al. The hematopoietic system-specific minor histocompatibility antigen HA-1 shows aberrant expression in epithelial cancer cells. J Exp Med 196 3 (2002) 359-368
6. Verdonck L.F., et al. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma. Blood 90 10 (1997) 4201-4205
7. Fefer A., et al. Graft versus leukemia effect in man: the relapse rate of acute leukemia is lower after allogeneic than after syngeneic marrow transplantation. Prog Clin Biol Res 244 (1987) 401-408
8. Weiden P.L., et al. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 304 25 (1981) 1529-1533
9. Maraninchi D., et al. Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias. Lancet 2 8552 (1987) 175-178
10. Childs R., et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 94 9 (1999) 3234-3241
11. Kolb H.J., and Holler E. Adoptive immunotherapy with donor lymphocyte transfusions. Curr Opin Oncol 9 2 (1997) 139-145
12. Tykodi S.S., et al. Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens. Clin Cancer Res 10 23 (2004) 7799-7811
13. Eibl B., et al. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 88 4 (1996) 1501-1508
14. Kolb H.J., et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76 12 (1990) 2462-2465
15. Lokhorst H.M., et al. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 90 10 (1997) 4206-4211
16. Childs R., et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343 11 (2000) 750-758
17. Moscovitch M., and Slavin S. Anti-tumor effects of allogeneic bone marrow transplantation in (NZB X NZW)F1 hybrids with spontaneous lymphosarcoma. J Immunol 132 2 (1984) 997-1000
18. Morecki S., et al. Induction of graft vs. tumor effect in a murine model of mammary adenocarcinoma. Int J Cancer 71 1 (1997) 59-63
19. Ben-Yosef R., et al. Graft-versus-tumour and graft-versus-leukaemia effect in patient with concurrent breast cancer and acute myelocytic leukaemia. Lancet 348 9036 (1996) 1242-1243
20. Rini B.I., et al. Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J Clin Oncol 20 8 (2002) 2017-2024
21. Artz A.S., et al. Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience. Bone Marrow Transplant 35 3 (2005) 253-260
22. Bregni M., et al. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 99 11 (2002) 4234-4236
23. Pedrazzoli P., et al. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies. Cancer 94 9 (2002) 2409-2415
24. Blaise D., et al. Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. Blood 103 2 (2004) 435-441
25. Nakagawa T., et al. Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for treatment of metastatic renal cell carcinoma: single institution experience with a minimum 1-year follow-up. Exp Hematol 32 7 (2004) 599-606
26. Ueno N.T., et al. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 102 10 (2003) 3829-3836
27. Hentschke P., et al. Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. Bone Marrow Transplant 31 4 (2003) 253-261
28. Massenkeil G., et al. Nonmyeloablative stem cell transplantation in metastatic renal cell carcinoma: delayed graft-versus-tumor effect is associated with chimerism conversion but transplantation has high toxicity. Bone Marrow Transplant 34 4 (2004) 309-316
29. Peccatori J., et al. Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation. Cancer 104 10 (2005) 2099-2103
30. Bishop M.R., et al. Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. J Clin Oncol 22 19 (2004) 3886-3892
31. Carella A.M., et al. Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer. Lancet 366 9482 (2005) 318-320
32. Bay J.O., et al. Allogeneic hematopoietic stem cell transplantation in ovarian carcinoma: results of five patients. Bone Marrow Transplant 30 2 (2002) 95-102
33. Hanel M., et al. Evidence for a graft-versus-tumor effect in refractory ovarian cancer. J Cancer Res Clin Oncol 129 1 (2003) 12-16
34. Takahashi T., et al. Nonmyeloablative allogeneic stem cell transplantation for patients with unresectable pancreatic cancer. Pancreas 28 3 (2004) pe65-pe69
35. Kanda Y., et al. Graft-versus-tumor effect against advanced pancreatic cancer after allogeneic reduced-intensity stem cell transplantation. Transplantation 79 7 (2005) 821-827
36. Zetterquist H., et al. A graft-versus-colonic cancer effect of allogeneic stem cell transplantation. Bone Marrow Transplant 28 12 (2001) 1161-1166
37. Srinivasan R., Barrett J., and Childs R. Allogeneic stem cell transplantation as immunotherapy for nonhematological cancers. Semin Oncol 31 1 (2004) 47-55
38. Bregni M., et al. Allogeneic stem cell transplantation for the treatment of advanced solid tumors. Springer Semin Immunopathol 26 1-2 (2004) 95-108
39. Burdach, S, et al., Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup study EICESS. Stem-Cell Transplant Programs at Dusseldorf University Medical Center, Germany and St. Anna Kinderspital, Vienna, Austria. Ann Oncol, 2000; 11(11): p. 1451-62.
40. Castagna L., et al. Lack of activity of allogeneic stem cell transplantation with reduced-intensity conditioning regimens in advanced sarcomas. Bone Marrow Transplant 35 4 (2005) 421-422
41. Hori A., et al. Urgent need for a validated tumor response evaluation system for use in immunotherapy. Bone Marrow Transplant 33 2 (2004) 255-256 author reply 257-8
42. Fuchs E.J., and Whartenby K.A. Hematopoietic stem cell transplant as a platform for tumor immunotherapy. Curr Opin Mol Ther 6 1 (2004) 48-53
43. Solomon S.R., et al. Optimized clinical-scale culture conditions for ex vivo selective depletion of host-reactive donor lymphocytes: a strategy for GvHD prophylaxis in allogeneic PBSC transplantation. Cytotherapy 4 5 (2002) 395-406
44. Amrolia P.J., et al. Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood 102 6 (2003) 2292-2299